Ratings GlaxoSmithKline Pharmaceuticals Limited

Equities

500660

INE159A01016

Market Closed - Bombay S.E. Other stock markets 06:00:50 2024-04-19 am EDT			5-day change	1st Jan Change
1,869 ^INR	-1.08%		-0.81%	-1.50%

Mar. 22	GlaxoSmithKline Pharmaceuticals Limited Receives Orders from Government Authorities	CI
Feb. 29	Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14%	MT

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46.49 times its estimated earnings per share for the ongoing year.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Revenue estimates are regularly revised downwards for the current and coming years.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED	-1.50%	3.83B	C+
ELI LILLY AND COMPANY	+24.60%	672B	C+
NOVO NORDISK A/S	+24.08%	550B	B
JOHNSON & JOHNSON	-5.63%	351B	C+
MERCK & CO., INC.	+15.37%	317B	B-
ABBVIE INC.	+7.38%	292B	C+
ASTRAZENECA PLC	+3.26%	211B	B+
NOVARTIS AG	+0.78%	203B	B-
PFIZER, INC.	-9.69%	144B	C+
AMGEN INC.	-6.63%	141B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes